ERBB2 and breast cancer: To this end we used our landscape model genes to interrogate data from the recently published Cell Line Encyclopedia [31], which includes both gene expression (Affymetrix arrays) and sensitivity (EC50) to the HER2 small molecule tyrosine kinase inhibitor lapatinib in 18 established breast cancer cell lines.